arrow
L

Line Bjørge

department of obstetrics and gynecology, haukeland university hospital, bergen, norway
H指数:51
被引数:9,155

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer

398,238名女性的全基因组关联研究揭示了七个与高级别浆液性卵巢癌相关的位点

2025-11-200
OAAI
A plain language summary publication of patients’ survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel

一份关于接受多塔利单抗联合卡铂-紫杉醇治疗子宫内膜癌患者生存情况的通俗语言摘要出版物

2025-10-090
OA
Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors

泛癌种唾液酸Tn靶向扩展了CAR疗法在实体瘤中的应用

2025-09-080
OAAI
Empowerment and quality of life in gynecological cancer survivors: Outcomes from a multicenter quasi-experimental cohort study from Norway (the LETSGO trial)

赋能和生活质量在妇科癌症幸存者中的研究:来自挪威一项多中心准实验队列研究(LETSGO试验)的结果

Cancer
IF5.1
2025-08-080
PREAI
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients

一项关于tilvestamab(BGB149)在复发、铂耐药、高级别浆液性卵巢癌(PROC)患者中的1b期、多中心、剂量递增、安全性和药代动力学研究

2025-07-220
OAAI
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer

关于晚期卵巢癌维持治疗方案选择和护理模式的驱动因素共识

2025-04-190
OA
Hereditary antithrombin deficiency and venous thrombosis in pregnancy–results of a retrospective multicenter study

遗传性抗凝血酶缺乏症与妊娠期静脉血栓形成——一项回顾性多中心研究的结果

2025-03-120
PRE
Palbociclib plus letrozole in estrogen receptor-positive advanced/ recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial

帕博西利联合来曲唑在雌激素受体阳性晚期/复发性子宫内膜癌中的应用:双盲安慰剂对照随机II期ENGOT-EN3/PALEO试验

2025-01-011
OAAI
Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy

ENGOT-EN6-NSGO/GOG-3031/RUBY试验中接受随访免疫治疗的局部晚期或复发性子宫内膜癌(pA/rEC)患者的术后进展生存结局。

2024-09-010
PRE
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel- paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial
2024-08-014
OA
Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions

整合多组学分析以确定卵巢癌风险区域的遗传和功能机制

2024-06-016
PRE